Kuros Biosciences Reports First US and UK Sales of MagnetOs

Kuros Biosciences announced the first commercial uses of MagnetOs bone graft substitute in the U.S. and U.K., in spinal fusion and scoliosis procedures, respectively.
Kuros received FDA 510(k) clearance to market MagnetOs putty as an autograft extender in the posterolateral spine in 3Q17, and gained approval under the CE Mark earlier this year....

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us